SIGLEC15 and cancer: Therefore, Siglec15 is considered a promising new target for normalization cancer immunotherapy independent of the PD-1/PD-L1 pathway, and targeting Siglec15 may be an effective alternative therapy for patients who do not respond to PD-1/PD-L1 antibodies 16-18.